Report Information More information from: https ://www.wis eguyreports .com/reports /495869
Acute Coronary Syndrome - Pipeline Review, H1 2016 Report / Search Code: WGR495869
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Acute Coronary Syndrome - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Acute Coronary Syndrome - Pipeline Review, H1 2016’, provides an overview of the Acute Coronary Syndrome pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Acute Coronary Syndrome, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Acute Coronary Syndrome - The report reviews pipeline therapeutics for Acute Coronary Syndrome by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Acute Coronary Syndrome therapeutics and enlis ts all their major and minor projects - The report as s es s es Acute Coronary Syndrome therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Acute Coronary Syndrome Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Acute Coronary Syndrome - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 6 Lis t of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Coronary Syndrome Overview 9 Therapeutics Development 10 Pipeline Products for Acute Coronary Syndrome - Overview 10 Acute Coronary Syndrome - Therapeutics under Development by Companies 11 Acute Coronary Syndrome - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Acute Coronary Syndrome - Products under Development by Companies 15 Acute Coronary Syndrome - Companies Involved in Therapeutics Development 16 advanceCor GmbH 16 Arena Pharmaceuticals , Inc. 17 Artery Therapeutics , Inc. 18 Athera Biotechnologies AB 19 Bayer AG 20 Cardiome Pharma Corp. 21 Cerenis Therapeutics Holding SA 22 CSL Limited 23 Es perion Therapeutics , Inc. 24 GlaxoSmithKline Plc 25 Japan Tobacco Inc. 26 Lee's Pharmaceutical Holdings Limited 27 MedImmune, LLC 28 Pfizer Inc. 29 The Medicines Company 30 Acute Coronary Syndrome - Therapeutics As s es s ment 31 As s es s ment by Monotherapy Products 31 As s es s ment by Target 32 As s es s ment by Mechanis m of Action 34 As s es s ment by Route of Adminis tration 36 As s es s ment by Molecule Type 38 Drug Profiles 40 4-WF - Drug Profile 40 Product Des cription 40 Mechanis m of Action 40 R& D Progres s 40 AEM-28 - Drug Profile 41 Product Des cription 41 Mechanis m of Action 41 R& D Progres s 41 AEM-2802 - Drug Profile 42 Product Des cription 42 Mechanis m of Action 42 R& D Progres s 42 Artpep-2 - Drug Profile 43 Product Des cription 43 Mechanis m of Action 43 R& D Progres s 43 Biologics for Acute Coronary Syndrome - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 CER-001 - Drug Profile 45 Product Des cription 45 Mechanis m of Action 45 R& D Progres s 45 COR-2 - Drug Profile 48 Product Des cription 48 Mechanis m of Action 48 R& D Progres s 48 COR-3 - Drug Profile 49 Product Des cription 49 Mechanis m of Action 49
R& D Progres s 49 CSL-112 - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50 dalcetrapib - Drug Profile 52 Product Des cription 52 Mechanis m of Action 52 R& D Progres s 52 los mapimod - Drug Profile 55 Product Des cription 55 Mechanis m of Action 55 R& D Progres s 55 MDCO-216 - Drug Profile 57 Product Des cription 57 Mechanis m of Action 57 R& D Progres s 57 MEDI-6012 - Drug Profile 59 Product Des cription 59 Mechanis m of Action 59 R& D Progres s 59 PC-mAb - Drug Profile 61 Product Des cription 61 Mechanis m of Action 61 R& D Progres s 61 PF-06282999 - Drug Profile 63 Product Des cription 63 Mechanis m of Action 63 R& D Progres s 63 PMC-6 - Drug Profile 64 Product Des cription 64 Mechanis m of Action 64 R& D Progres s 64 PR-15 - Drug Profile 65 Product Des cription 65 Mechanis m of Action 65 R& D Progres s 65 rivaroxaban - Drug Profile 67 Product Des cription 67 Mechanis m of Action 67 R& D Progres s 67 temanogrel hydrochloride - Drug Profile 73 Product Des cription 73 Mechanis m of Action 73 R& D Progres s 73 tirofiban hydrochloride - Drug Profile 75 Product Des cription 75 Mechanis m of Action 75 R& D Progres s 75 Z K-001 - Drug Profile 76 Product Des cription 76 Mechanis m of Action 76 R& D Progres s 76 Acute Coronary Syndrome - Recent Pipeline Updates 78 Acute Coronary Syndrome - Dormant Projects 100 Acute Coronary Syndrome - Dis continued Products 102 Acute Coronary Syndrome - Product Development Miles tones 104 Featured News & Pres s Releas es 104 Apr 26, 2016: DalCor Randomizes Firs t Patient in the DalGenE Phas e 3 Cardiovas cular Outcomes Trial 104 Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 105 Feb 23, 2016: Meta-Analys is of AGGRASTAT (Tirofiban HCl) Pres ented at CRT 2016 Conference 105 Dec 14, 2015: The Medicines Company Announces Inves tigational Lipid Modulating Agent, MDCO-216, Phas e 1 Data Publis hed in European Heart JournalCardiovas cular Pharmacotherapy 105 Nov 10, 2015: Cerenis Therapeutics : New Data for CER-001 Pres ented in Key Oral Ses s ion at American Heart As s ociation Conference 2015 107 Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (los mapimod cardiovas cular s tudy) 108 Sep 08, 2015: Firs t patients enter phas e II CARAT trial to as s es s reduction in atheros clerotic plaque us ing CER-001 in pos t Acute Coronary Syndrome (ACS) patients 108 Jul 23, 2015: Caps tone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 110 Jun 08, 2015: DalCor Pharma licens es a late-s tage inves tigational cardiovas cular drug following major s cientific dis covery 111 May 11, 2015: Xarelto Bleeding Laws uit Judge Orders the Selection of Cas es for
Dis covery, Reports Xarelto Laws uit Funding Firm, Fair Rate Funding 112 Appendix 113 Methodology 113 Coverage 113 Secondary Res earch 113 Primary Res earch 113 Expert Panel Validation 113 Contact Us 113 Dis claimer 114 Lis t of Tables Number of Products under Development for Acute Coronary Syndrome, H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Comparative Analys is by Late Stage Development, H1 2016 12 Comparative Analys is by Clinical Stage Development, H1 2016 13 Comparative Analys is by Early Stage Development, H1 2016 14 Products under Development by Companies , H1 2016 15 Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H1 2016 16 Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals , Inc., H1 2016 17 Acute Coronary Syndrome - Pipeline by Artery Therapeutics , Inc., H1 2016 18 Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H1 2016 19 Acute Coronary Syndrome - Pipeline by Bayer AG, H1 2016 20 Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H1 2016 21 Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 22 Acute Coronary Syndrome - Pipeline by CSL Limited, H1 2016 23 Acute Coronary Syndrome - Pipeline by Es perion Therapeutics , Inc., H1 2016 24 Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2016 25 Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H1 2016 26 Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 27 Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H1 2016 28 Acute Coronary Syndrome - Pipeline by PďŹ zer Inc., H1 2016 29 Acute Coronary Syndrome - Pipeline by The Medicines Company, H1 2016 30 As s es s ment by Monotherapy Products , H1 2016 31 Number of Products by Stage and Target, H1 2016 33 Number of Products by Stage and Mechanis m of Action, H1 2016 35 Number of Products by Stage and Route of Adminis tration, H1 2016 37 Number of Products by Stage and Molecule Type, H1 2016 39 Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates , H1 2016 78 Acute Coronary Syndrome - Dormant Projects , H1 2016 100 Acute Coronary Syndrome - Dormant Projects (Contd..1), H1 2016 101 Acute Coronary Syndrome - Dis continued Products , H1 2016 102 Acute Coronary Syndrome - Dis continued Products (Contd..1), H1 2016 103 Lis t of Figures Number of Products under Development for Acute Coronary Syndrome, H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Comparative Analys is by Clinical Stage Development, H1 2016 13 As s es s ment by Monotherapy Products , H1 2016 31 Number of Products by Top 10 Targets , H1 2016 32 Number of Products by Stage and Top 10 Targets , H1 2016 32 Number of Products by Top 10 Mechanis m of Actions , H1 2016 34 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 34 Number of Products by Routes of Adminis tration, H1 2016 36 Number of Products by Stage and Routes of Adminis tration, H1 2016 36 Number of Products by Top 10 Molecule Types , H1 2016 38 Number of Products by Stage and Top 10 Molecule Types , H1 2016 38
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349